Core Viewpoint - Fosen Pharmaceutical has received approval from the National Medical Products Administration of China for its Metformin and Empagliflozin Tablets (I), aimed at improving blood sugar control in adult patients with type 2 diabetes [1][2]. Group 1: Product Details - The Metformin and Empagliflozin Tablets (I) are a combination formulation of Metformin hydrochloride and Empagliflozin, which work synergistically to enhance glucose control compared to standard monotherapy [1]. - Metformin reduces hepatic glucose production, inhibits intestinal glucose absorption, and increases peripheral glucose uptake, thereby improving insulin sensitivity [1]. - Empagliflozin, an SGLT2 inhibitor, decreases renal glucose reabsorption, lowers renal glucose threshold, and promotes glucose excretion through urine [1]. Group 2: Market Context - The National Health Commission of China has set a target for 2025, aiming for a 70% management rate and knowledge awareness rate among diabetes patients, indicating a growing demand for diabetes medications [2]. - The Metformin and Empagliflozin Tablets (I) are classified as a Category B drug under medical insurance, offering advantages such as effective glucose-lowering effects and good patient tolerance without serious adverse reactions [2]. - Bioequivalence studies have shown that the product is consistent with the reference formulation, supporting its efficacy in improving blood sugar control in adult patients with type 2 diabetes [2]. Group 3: Strategic Importance - The company views the Metformin and Empagliflozin Tablets (I) as a significant addition to its product pipeline in the diabetes treatment sector, providing more treatment options for patients [2].
福森药业(01652.HK)：二甲双胍恩格列净片(I)获批上市